CSIMarket Company Name, Ticker, Industry, else..
 
Dmk Pharmaceuticals Corporation  (NASDAQ: DMK)
Other Ticker:  
 
 
Price: $0.2320 $0.00 0.913%
Day's High: $0.49 Week Perf: -57.04 %
Day's Low: $ 0.18 30 Day Perf: -65.93 %
Volume (M): 24,158 52 Wk High: $ 0.00
Volume (M$): $ 5,605 52 Wk Avg: $0.00
Open: $0.18 52 Wk Low: $0.00



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Dmk Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a multinational pharmaceutical company headquartered in New York, USA. The company specializes in the research, development, manufacturing, and distribution of various pharmaceutical products. Established in 1995, DMK Pharmaceuticals has a diverse range of medications in its portfolio, including prescription drugs, over-the-counter medicines, and generic pharmaceuticals. The company focuses on delivering high-quality and affordable healthcare solutions to improve patient outcomes. With a strong commitment to innovation and customer satisfaction, DMK Pharmaceuticals has become a trusted name in the pharmaceutical industry.


   Company Address: 11622 El Camino Real San Diego 92130 CA
   Company Phone Number: 997-2400   Stock Exchange / Ticker: NASDAQ DMK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        9.33% 
BMY   -2.13%    
JNJ   -1.49%    
LLY        8.22% 
MRK        6.28% 
PFE        3.99% 
• View Complete Report
   



Contract

DMK Pharmaceuticals Resurges with ZIMHI Rights and Seeks Lucrative Global Partnerships to Drive Revenue Growth

Published Thu, Dec 21 2023 1:15 PM UTC

DMK Pharmaceuticals Secures Full Rights to Commercialize ZIMHI and Seeks Lucrative PartnershipsIn a strategic move to expand revenue generation, DMK Pharmaceuticals has successfully regained full rights to commercialize their highly anticipated product, ZIMHI. This significant development allows the company to establish a stronger foothold in the pharmaceutical market and pu...
Dmk Pharmaceuticals Corporation

DMK Pharmaceuticals Corporation Faces Financial Turmoil as Revenue Plummets and Losses Soar, But a Glimmer of Hope Emerges



DMK Pharmaceuticals Corporation recently reported its financial results for the quarter ending September 30, 2023, and the numbers paint a bleak picture. With revenue plummeting by -99.398% to $0.01 million and net loss per share increasing to $-0.20 compared to the same quarter last year, the company is facing significant challenges. However, amidst the financial woes, they have also shared updates on their research and development activities in the field of neuro-biotechnology. Let's delve deeper into the details.
Financial Performance:
In the third quarter of 2023, DMK Pharmaceuticals Corporation's revenue experienced an alarming decline of -99.398%, dropping to only $0.01 million. This represents a sharp contrast to the comparable quarter from the previous year. Net loss per share during this period soared to $-0.20, highlighting the financial struggles the company is currently grappling with. However, there is a glimmer of hope in the sequential growth of revenue, which increased by 30.482% compared to the prior quarter.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com